Michael Christel

Oct 31, 2024 | pharmaceuticalcommerce.com | Marina Crouse |Michael Christel

Pharmacies, most agree, are no longer simply just a place to pick up a filled prescription. Even before the COVID-19 pandemic, pharmacy services had begun to expand. The public health crisis, however, would thrust community pharmacies in the US into the spotlight, and they responded. Their offerings—and the reliance on them—exploded. Seemingly overnight, retail and community/independent pharmacies introduced virus testing clinics for COVID, then vaccination distributions at a large scale.

Apr 2, 2024 | pharmaceuticalcommerce.com | Michael Christel

PC: How are large pharma companies adapting their strategies in product lifecycle management and portfolio development in the face looming headwinds such as the 2030 patent cliff? Tritschler: This adaption in lifecycle management and portfolio development by large pharmaceutical companies is currently top of mind and a key priority for many leaders in the pharmaceutical industry. The 2030 patent cliff is a real thing.

Mar 29, 2024 | pharmaceuticalcommerce.com | Michael Christel

PC: Which therapeutics settings, or technology/platform areas, are you seeing the most M&A and partnering activity at the moment? Tritschler: There are several therapeutic areas and technology platforms where we’ve seen a very strong focus in 2023 and the first few months of this year. In terms of TA, oncology is still, by far, ahead regarding deal volumes compared to all the other therapeutic areas. But then we see neurology and cardiology also being very relevant at the moment.

Mar 19, 2024 | pharmaceuticalcommerce.com | Michael Christel

PC: What steps can young innovator companies take to better differentiate their value proposition and attract interest from potential buyers? Tritschler: The early-stage companies are phenomenal in one area—they have a great understanding of the clinical value of their asset. The key problem is not the clinical side of things, but more the commercial and market access side that a lot of these young companies are not sufficiently focusing on.

Mar 18, 2024 | pharmaceuticalcommerce.com | Michael Christel

PC: Amid a seemingly more risk-averse investment and funding climate, has it become increasingly difficult for startup or emerging life sciences companies to justify the value of their early-stage assets? Tritschler: Last year was probably, compared to the boom years before, where everything was bought more out of this fear-of-missing-out; and very positive valuations were taken where everything would have needed to fit perfectly in order to earn this investment back later on.